The Pancreatic Cancer Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Pancreatic Cancer Market is estimated to be USD 2.41 billion in 2018 and predicted to rise to USD 3.47 billion by 2023 with a CAGR of 7.54%. The market is segmented based on the type of treatment into surgery, chemotherapy, radiation therapy and others. By type, the market has been further segmented as exocrine pancreas cancer and endocrine pancreas cancer. And by end users as hospitals, clinics, research institutes and others. Furthermore, based on geography the market is segmented into various regions namely North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
The pancreatic cancer market has one of the highest unmet therapeutic needs in the oncology market across the globe with less than five-year survival. This is also the most challenging aspect that this market needs to address. Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Adenocarcinomas, constitutes nearly 95% of all the exocrine pancreatic cancers and is the most common type of pancreatic cancer. Other widespread cancer types of the pancreas that affect endocrine functions are adenosquamous carcinomas, squamous cell carcinomas, and giant cell carcinomas.
As of now, North America region dominates the pancreatic cancer market. Europe comes next. However, the Asia-Pacific stem cell therapy market is expected to grow the fastest in this forecast period.
Key players in the pancreatic cancer market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/” and checkout our recent reports in the Therapeutics category at “http://www.marketdataforecast.com/research-reports/healthcare/therapeutics-11/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.